A Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) in India (MK-7962-037)

Inclusion Criteria:

The main inclusion criteria include but are not limited to the following:

• Has documented historical diagnostic right heart catheterization (RHC), with the diagnosis of pulmonary arterial hypertension (PAH), also known as Group 1 pulmonary hypertension (PH), in any of the following subtypes: Idiopathic PAH, Heritable PAH, Drug/toxin-induced PAH, PAH associated with connective tissue disease, and PAH associated with simple, congenital systemic-to-pulmonary shunts at least 1 year following repair
• Has been on stable doses of PAH background therapies and diuretics (if applicable)
• Has symptomatic PAH classified as World Health Organization (WHO) Functional Classification (FC) II or III

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

• Has a diagnosis of Groups 2, 3, 4, or 5 PH
• Has a diagnosis of the following PAH (Group 1 PH) subtypes: human immunodeficiency virus (HIV)-associated PAH, PAH associated with portal hypertension, schistosomiasis-associated PAH, PAH diagnosed with pulmonary veno occlusive disease (PVOD) or pulmonary capillary hemangiomatosis (PCH)
• Has uncontrolled systemic hypertension
• Has a history of full or partial pneumonectomy
• Has untreated more than mild obstructive sleep apnea
• Has known history of portal hypertension or chronic liver disease, including hepatitis B and/or hepatitis C
• Has a history of restrictive, constrictive, or congestive cardiomyopathy
• Has significant mitral regurgitation or aortic regurgitation valvular disease, mitral stenosis, and more than mild aortic valve stenosis
• Has known malignancy that is progressing or has required active treatment within the past 5 years